Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kimberly A Dornbrook-Lavender"'
Autor:
Melanie S. Joy, Cynthia J. Denu-Ciocca, Susan L. Hogan, Kimberly A Dornbrook-Lavender, Hyunsook Chin, John A. Pieper
Publikováno v:
Pharmacotherapy. 25:335-344
Study Objectives. To determine the effects of atorvastatin on low-density lipoprotein cholesterol (LDL) particle size and C-reactive protein (CRP) concentrations in patients undergoing long-term hemodialysis. Another objective was to compare the effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caa0f4db89890a847c498f8a074c8789
https://doi.org/10.1592/phco.25.3.335.61599
https://doi.org/10.1592/phco.25.3.335.61599
Publikováno v:
Cardiovascular Drugs and Therapy. 17:75-82
Current strategies for both the primary and secondary prevention of coronary heart disease (CHD) focus on the traditional risk factors, such as hypertension, smoking cessation, and cholesterol, as the primary determinants of the cardiac risk profile,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::453a08218a4a26a4b61c1ef6436ab79e
https://doi.org/10.1023/a:1024212026578
https://doi.org/10.1023/a:1024212026578
Autor:
Yichun Hu, Tammy Boyette, Tandrea Hilliard, Melanie S. Joy, Corina Candiani, Susan L. Hogan, Joyce Blaisdell, Kimberly A Dornbrook-Lavender, Joyce A. Goldstein, Ronald J. Falk
Losartan is used for anti-proteinuric as well as blood pressure effects in chronic kidney disease (CKD). It is metabolized by cytochrome P450 (CYP) 2C9 to active E-3174. Single nucleotide polymorphisms in CYP2C9 that reduce catalytic activity could r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c01b72f221d517791859189f1e5635a0
Autor:
Cynthia J. Denu-Ciocca, Kimberly A Dornbrook-Lavender, Hyunsook Chin, Melanie S. Joy, Susan L. Hogan
Publikováno v:
The Annals of pharmacotherapy. 42(1)
Background: Dialysis patients have many underlying traditional and nontraditional risk factors that may predispose them to a high prevalence of cardiovascular disease. The effects of statins (eg, atorvastatin) on altering nontraditional lipoprotein m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6c18744039dda1e19bf7406947e8b26
https://pubmed.ncbi.nlm.nih.gov/18000162
https://pubmed.ncbi.nlm.nih.gov/18000162
Publikováno v:
The Annals of pharmacotherapy. 37(12)
To review relevant literature supporting the use of aspirin, beta-blockers, lipid-lowering agents, and angiotensin-converting enzyme (ACE) inhibitors for the secondary prevention of coronary heart disease (CHD) in an elderly patient population aged/=
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e254b32cf8cd98a58e32b5650f69baa0
https://pubmed.ncbi.nlm.nih.gov/14632542
https://pubmed.ncbi.nlm.nih.gov/14632542
Publikováno v:
The Annals of pharmacotherapy. 37(11)
OBJECTIVE: To review relevant literature supporting the use of antihypertensive agents, lipid-lowering agents (i.e., statins), and aspirin therapy for the primary prevention of coronary heart disease (CHD) in an elderly patient population (age ≥65
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eff8b4b115d5e312f5b515731097e813
https://pubmed.ncbi.nlm.nih.gov/14565805
https://pubmed.ncbi.nlm.nih.gov/14565805
Publikováno v:
Cardiovascular drugs and therapy. 17(1)
Current strategies for both the primary and secondary prevention of coronary heart disease (CHD) focus on the traditional risk factors, such as hypertension, smoking cessation, and cholesterol, as the primary determinants of the cardiac risk profile,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::15d0d2f61367c1acbe2ae12134dc8e99
https://pubmed.ncbi.nlm.nih.gov/12843689
https://pubmed.ncbi.nlm.nih.gov/12843689